ATNM:NYE-Actinium Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 8.51

Change

0.00 (0.00)%

Market Cap

USD 0.17B

Volume

0.11M

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19 CAR T-cell therapy with memorial sloan kettering cancer center. The company is also developing a multi-disease, multi-target pipeline of clinical-stage antibody radiation-conjugates targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a range of hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma. Actinium Pharmaceuticals, Inc. has research collaboration with Astellas Pharma, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platforms. The company was founded in 2000 and is based in New York, New York.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-13 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

N/A

USD194.29B 28.05 3.24
BHVN Biohaven Pharmaceutical Holdin..

N/A

USD6.83B N/A N/A
MYOV Myovant Sciences Ltd

N/A

USD2.07B N/A N/A
RCUS Arcus Biosciences, Inc

N/A

USD1.77B N/A N/A
ZYME Zymeworks Inc

N/A

USD1.74B 300.20 N/A
ADCT ADC Therapeutics SA

N/A

USD1.70B -99,999.99 N/A
CVM CEL-SCI Corporation

N/A

USD0.88B N/A N/A
RFL Rafael Holdings, Inc

N/A

USD0.74B N/A N/A
ANVS Annovis Bio, Inc

N/A

USD0.63B -99,999.99 N/A
LCTX Lineage Cell Therapeutics, Inc

N/A

USD0.47B 3.63 N/A

ETFs Containing ATNM

Symbol Name Weight Mer Price(Change) Market Cap
RJZ ELEMENTS Linked to the Ro.. 0.00 % 0.75 %

N/A

USD5.03M

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.10% 44% F 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.10% 44% F 43% F
Trailing 12 Months  
Capital Gain -36.96% 12% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -36.96% 12% F 3% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 20.41% 50% F 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.41% 50% F 82% B-
Risk Return Profile  
Volatility (Standard Deviation) 31.01% 81% B- 34% F
Risk Adjusted Return 65.83% 81% B- 76% C
Market Capitalization 0.17B 52% F 23% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.42 85% B 44% F
Price / Cash Flow Ratio -7.95 63% D 88% B+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -59.29% 58% F 9% F
Return on Invested Capital -65.97% 48% F 1% F
Return on Assets -33.07% 48% F 1% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 5.53 41% F 15% F
Short Percent 4.32% 52% F 44% F
Beta 1.06 63% D 51% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.